Upadacitinib Outperforms Dupilumab in Primary and Secondary End Points in Head-to-Head AD Study
In LEVEL-UP, upadacitinib demonstrated superiority over dupilumab in achieving EASI-90 and little to no itch at week 16.
In LEVEL-UP, upadacitinib demonstrated superiority over dupilumab in achieving EASI-90 and little to no itch at week 16.
Create a non-member account if you are appl ying for membership or need to interact with AAD systems. Non-member accounts do not have access to…
This case report describes multiple solitary open black comedones located bilaterally on the malar cheeks and temples as well as yellowish, smooth-surfaced papulonodular lesions in…
Create a non-member account if you are applying for membership or need to interact with AAD systems. Non-member accounts do not have access to the…
Publication: The Dermatologist Issue: Volume 32 – Issue 3 – April/May 2024 Created: Fri, 05/03/2024 – 11:15 Volume 32 Issue 3
May is Mental Health Awareness Month, and Dermatology Times is spotlighting the common relationship between skin conditions and struggles with mental health, quality of life,…
This consensus statement reports on the development of expert recommendations for treating vitiligo in pediatric, adolescent, and young adult patients in the US.
This case report describes an adult male patient with a severe acneiform eruption on his chest and back.
Supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. This 60-minute live and virtual symposium will include expert faculty engaged in a fast-paced,…
Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, comment on the newer treatments in AD, highlighting the positive impact these agents have had…
A new review highlighted JAK inhibitors’ role in vitiligo treatment, emphasizing varying benefits, facial efficacy, and potential for sustained responses.